ReviewNature reviews. Gastroenterology & hepatology2011
Controversies in the management of pancreatic IPMN.
Review in Nature reviews. Gastroenterology & hepatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts.The American journal of gastroenterology · 2018Guideline
- An Overview for Clinicians on Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas.Cancers · 2024Review
- Radiomics model versus 2017 revised international consensus guidelines for predicting malignant intraductal papillary mucinous neoplasms.European radiology · 2024Article
- Carbohydrate antigen 125 supplements carbohydrate antigen 19-9 for the prediction of invasive intraductal papillary mucinous neoplasms of the pancreas.World journal of surgical oncology · 2022Article
- The Role of Endoscopic Ultrasonography in the Diagnosis and Staging of Pancreatic Cancer.Cancers · 2022Review
- Could the burden of pancreatic cancer originate in childhood?World journal of gastroenterology · 2021Review
- Article
- Increased Risk of Second Primary Cancers Following Diagnosis of Malignant Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Population-Based Study.Frontiers in oncology · 2019Article
- Article
- An Appraisal of Current Guidelines for Managing Malignancy in Pancreatic Intraductal Papillary Mucinous Neoplasm.JOP : Journal of the pancreas · 2018Article
- Current best practice and controversies in the follow up of patients with asymptomatic branch duct IPMN of the pancreas.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2016Review
- Therapeutic Approach to Cystic Neoplasms of the Pancreas.Surgical oncology clinics of North America · 2016Review
- Sub-branch and mixed-type intraductal papillary mucinous neoplasms of the pancreas: 2 case reports.Radiology case reports · 2016Article
- Anaplastic carcinoma of the pancreas arising in an intraductal papillary mucinous neoplasm: A case report.Molecular and clinical oncology · 2016Article
- Intraductal papillary mucinous neoplasms of the pancreas: radiological predictors of malignant transformation and the introduction of bile duct dilation to current guidelines.The British journal of radiology · 2016Article
- What Is the Best Way to Identify Malignant Transformation Within Pancreatic IPMN: A Systematic Review and Meta-Analyses.Clinical and translational gastroenterology · 2015Article
- Intraductal papillary mucinous neoplasm in an annular pancreas: a case report.Surgical case reports · 2015Article
- International consensus on the management of intraductal papillary mucinous neoplasm of the pancreas.Annals of translational medicine · 2015Review
- Overweight increases the risk of malignancy in patients with pancreatic mucinous cystic neoplasms.Medicine · 2015Article
- Current roles of endoscopy in the management of intraductal papillary mucinous neoplasm of the pancreas.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although considerable progress has been made in our understanding of intraductal papillary mucinous neoplasm (IPMN) of the pancreas, some issues still remain to be resolved. Uncertainty exists regarding the classification of IPMNs. The necessity of the mixed-type category of IPMN and whether such lesions should be defined radiographically or histologically needs to be determined. The preoperative distinction of branch duct IPMNs from nonmucinous cysts should be further investigated so that potentially malignant lesions can be identified and management strategies guided effectively. The role and safety of cystic fluid analysis remains to be clarified in this context. With regard to the diagnosis of malignancy in branch duct IPMNs, criteria for identifying malignancy need to be re-evaluated. The presence of mural nodules is a very reliable predictor; however, controversy exists over the value of size as a reliable indicator. Criteria with increased specificity are needed, perhaps including histological subtype of lesion, to reduce the false-positive rate of the present criteria. Finally, the best modality and interval for surveillance of branch duct IPMNs requires determination because of its significance in terms of malignant transformation, development of distinct ductal adenocarcinoma and disease recurrence after resection.
Indexed as
Identifiers
21212775What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.